Annual results 2020: A thriving core business and razor-sharp biotech profile
Hørsholm, Denmark 28 May 2021
- Gubra achieves strong growth results in its core CRO business.
- New models in the Kidney Space and in 3D imaging well received by the market.
- New AI/ML-based peptide target and drug discovery platform enables Gubra to deliver unbiased synthesis and identification of new complex peptides at unprecedented speed.
On a backdrop of COVID-19, Gubra closes 2020 with a thriving core business and a promising outlook for 2021. At the end of the year, gross profit amounted to MDKK 134,9 MDKK. Pre-tax profits 20,3 MDKK.
In 2020, Gubra achieved strong growth results in its core CRO business. A constant focus on efficiency and digitalization enabled Gubra to deliver an increased number of quality data and studies, even with a slight decrease in employees.
Investments into new disease models in the Kidney space and in 3D imaging have expanded Gubra’s services portfolio, and both offerings have been well received by the market.
New proprietary peptide target and drug discovery platform
Although Gubra received fewer milestone payments than the year before, this was expected. Eyes and expectations are on the company’s newest advanced technological and scientific venture: the launch of an innovative proprietary peptide target and drug discovery platform – streaMLine preDict and streaMLine conclude. With this new AI/ML-based platform inter-digitizing with the chemistry wet-labs, Gubra can deliver unbiased design, synthesis and characterization of peptides at unprecedented speed.
A constant focus on digitalization, artificial intelligence, machine learning and robotization are key drivers in Gubra’s science and continual business transformation.
CEO of Gubra Henrik Blou is satisfied with the results and confident about the years to come:
“From a financial perspective 2020 was a year in top 3 for Gubra. Science-wise, we are talking about a record year in terms of discovery, digitalization, robotization and innovation. We are very satisfied with our achievements in the digital and technological field. Combining this with our strong scientific profile and competencies the outlook is incredible.”
CSR report 2020: Gubra reveals new ways to reducing carbon emissions
Already last year, when Gubra launched its first CSR report, the company was able to show a negative carbon footprint. This was possible through responsible and deliberate climate-focused efforts. In its newest CSR report, Gubra reveals new ways to reducing its carbon footprint. For instance, by reducing commute transportation emissions via greener and healthier ways for employees to get to work. Also, Gubra has expanded its forest and nature project on the Danish island of Langeland.
Henrik Blou, CEO
Phone: +45 2861 6845
Founded in 2008, Gubra is a privately-held biotech company located in Denmark delivering scientific counselling, contract research services, and projects for co-development in four main focus areas: Obesity, diabetes, NASH and diabetic complications. Gubra experts cover a number of pre-clinical disciplines: in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers by combining cutting-edge technology with our accumulated experience and proven methodology. For more information, please visit our website at www.gubra.dk
Rooted in the Gut-Brain Axis
Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We believe that the next great leap forward in treatment paradigms within obesity, diabetes and related metabolic disorders will be found in the interplay of the gut and the brain.